Long-term treatment with Enjaymo (sutimlimab) leads to sustained reductions in red blood cell destruction, anemia, and fatigue, as well as life quality improvements, in adults with cold agglutinin disease (CAD).
That’s according to data from the extension portion (Part B) of the global Phase…
[ad_2]
Source link
